Invivyd reports positive Phase 1/2 data for VYD2311 COVID-19 mAb; half-life up to 76 days

Invivyd, Inc.

All adverse events mild to moderate; no serious or severe AEs observed across IV, SC, and IM routes.
VYD2311 half-life by cohort: IM 76 days, high-dose IV 61 days, vs pemivibart's 49 days.
Dose modeling indicates IM dosing every 3 months may provide robust efficacy for immunocompromised and non-IC.
Type C meeting with FDA scheduled for early Q3 2025 to discuss registration path for VYD2311.
VYD2311 is 99%+ structurally identical to adintrevimab and pemivibart, with improved potency.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.